Early data from the ADAPT JR trial suggest efgartigimod may benefit adolescents with generalized myasthenia gravis, a rare condition with few effective treatment options.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/efgartigimod-promising-rare-pediatric-disease-few-treatment-2025a1000u97?src=rss
Author :
Publish date : 2025-11-04 06:47:00
Copyright for syndicated content belongs to the linked Source.